SOPHiA DDM GEN2

Analytical platform for clinical genomics that enables the detection, annotation, and interpretation of genomic variants using artificial intelligence to support patient diagnosis and treatment.

Detailed Description

SOPHiA DDM™ Platform is an advanced solution for precision medicine workflows, with a renewed interface, web access, and new functionalities to accelerate genomic data analysis. It offers end‑to‑end workflows for the detection, annotation, and pre‑classification of genomic variants from complex NGS data, facilitating decision‑making in oncology, rare diseases, and hereditary disorders.

SOPHiA DDM Platform

Principle of operation

SOPHiA DDM® is a web‑based platform powered by artificial intelligence designed for genomic data analysis, automatically performing quality control, alignment, and variant detection. It then executes a comprehensive variant annotation from multiple sources and pre‑classifies them into different pathogenicity categories. The platform facilitates interpretation through integrated databases and allows the generation of custom variant reports.

SOPHiA DDM principle of operation

Clinical applications

It is aimed at genomic analysis in oncology, rare diseases, and hereditary disorders. The platform is designed to facilitate rapid and confident decision‑making through the detection, annotation, and pre‑classification of genomic variants.

Benefits

In genomics, the platform helps overcome bottlenecks by:

Seamless integration of clinical genomics workflows, reducing operational barriers thanks to its web access, single workspace, and new interface. Prioritisation of variants, simplification of interpretation, and acceleration of reporting. AI and machine learning algorithms aimed at increasing positive findings and improving confidence in the analysis of complex variants.

Intended user / audience

Solution aimed at clinical genomics laboratories, healthcare institutions, and precision medicine teams that need to integrate genomic analysis workflows in areas such as oncology, rare diseases, and hereditary disorders, with the ability to work in IVD or RUO environments depending on the application and the corresponding mode of use.

Key Features

SaaS platform for clinical genomic analysis based on artificial intelligence Automatic detection, annotation and pre‑classification of genetic variants Integration with multiple databases for proper management of identified variants Generation of customised and clinically actionable reports Access to a global community of genomics experts High security and data encryption in compliance with international regulations Intuitive and easy‑to‑use interface with fast response time
×

Area:

Molecular Genetics, Software, Software solutions for germline analysis

Technology:

Consult our experts

Google reCaptcha: Invalid site key.

Related products

SureSelect Cancer CGP Assay

Targeted-enrichment NGS pan-cancer panel for comprehensive genomic profiling (CGP) of solid tumours. Designed to detect somatic variants at DNA level (SNVs, indels, CNVs, translocations) and RNA level (gene fusions), as well as to assess complex immuno-oncology biomarkers such as tumour mutational burden (TMB), microsatellite instability (MSI) and homologous recombination deficiency (HRD). Detailed Description Operating principle…
Agilent
Next Generation Sequencing (NGS)

SeqOne HRD Solution con Agilent SureSelect CD HRR17 Panel

HRD analysis solution combining low-coverage whole-genome sequencing (shallow/low-pass WGS) and a targeted gene panel to detect genomic instability, BRCA1/2 alterations and other genes related to homologous recombination. It is designed for laboratories wishing to implement HRD testing in-house with an automated, efficient and clinically validated workflow. Detailed Description SeqOne’s HRD solution combines shallow WGS and…
Agilent
Next Generation Sequencing (NGS)

OncoSELECT®

Comprehensive targeted liquid biopsy assay designed to support decision-making in oncology through the analysis of 74 clinically relevant genes. The solution encompasses everything from library preparation reagents to bioinformatics analysis, clinical interpretation and the generation of detailed reports. 3.- Detailed Description Operating principle OncoSELECT® is an advanced liquid biopsy panel based on circulating cell-free DNA…
OncoDNA
Next Generation Sequencing (NGS)

Agilent SureSelect Human All Exon V8.

High-performance exome for the enrichment of human coding regions, with updated coverage of RefSeq, CCDS and GENCODE, including the TERT promoter and difficult-to-capture exons. 3.- Detailed Description Operating principle SureSelect Human All Exon V8 is based on NGS library preparation and capture enrichment of target regions of the human exome. The workflow is compatible with…
Agilent
Next Generation Sequencing (NGS)